Literature DB >> 25663486

Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).

Ronald A Simon1, Kristen M Dazy, Jeremy D Waldram.   

Abstract

Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs). A provocative aspirin challenge is the gold standard for diagnosis of AERD. Aspirin desensitization and continuous aspirin therapy has been highly efficacious in those patients with suboptimal control of their disease on current available pharmacotherapy or those with other underlying conditions (i.e., cardiovascular disease) who may require frequent treatment with aspirin or NSAIDs. This review article focuses on aspirin desensitization and the management of patients with AERD with a particular emphasis on outcomes in those patients with chronic rhinosinusitis and nasal polyposis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25663486     DOI: 10.1007/s11882-014-0508-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  52 in total

1.  Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.

Authors:  Pär Gyllfors; Grazyna Bochenek; John Overholt; Diane Drupka; Maria Kumlin; James Sheller; Ewa Nizankowska; Peter C Isakson; Filip Mejza; James B Lefkowith; Sven-Erik Dahlén; Andrew Szczeklik; John J Murray; Barbro Dahlén
Journal:  J Allergy Clin Immunol       Date:  2003-05       Impact factor: 10.793

2.  The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.

Authors:  M P Berges-Gimeno; R A Simon; D D Stevenson
Journal:  Clin Exp Allergy       Date:  2002-10       Impact factor: 5.018

3.  Aspirin desensitization for ASA triad patients--prospective study of the rhinologist`s perspective.

Authors:  B Forer; S Kivity; J Sade; R Landsberg
Journal:  Rhinology       Date:  2011-03       Impact factor: 3.681

4.  Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.

Authors:  Eric Macy; Jonathan A Bernstein; Mariana C Castells; Sandra M Gawchik; Tak H Lee; Russell A Settipane; Ronald A Simon; Jeffrey Wald; Katharine M Woessner
Journal:  Ann Allergy Asthma Immunol       Date:  2007-02       Impact factor: 6.347

5.  An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.

Authors:  Marcus Shaker; Ano Lobb; Pamela Jenkins; Daniel O'Rourke; Steve K Takemoto; Salil Sheth; Thomas Burroughs; Mark S Dykewicz
Journal:  J Allergy Clin Immunol       Date:  2007-08-22       Impact factor: 10.793

Review 6.  Aspirin and NSAID sensitivity.

Authors:  Donald D Stevenson
Journal:  Immunol Allergy Clin North Am       Date:  2004-08       Impact factor: 3.479

7.  Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization.

Authors:  John W Steinke; Jeffrey A Culp; Elizabeth Kropf; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2009-09-19       Impact factor: 10.793

8.  Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma.

Authors:  N Ogata; Y Darby; G Scadding
Journal:  J Laryngol Otol       Date:  2007-08-15       Impact factor: 1.469

9.  Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease.

Authors:  K Fruth; B Pogorzelski; I Schmidtmann; J Springer; N Fennan; N Fraessdorf; A Boessert; D Schaefer; J Gosepath; W J Mann
Journal:  Allergy       Date:  2013-03-07       Impact factor: 13.146

10.  Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.

Authors:  A R Fischer; M A Rosenberg; C M Lilly; J C Callery; P Rubin; J Cohn; M V White; Y Igarashi; M A Kaliner; J M Drazen
Journal:  J Allergy Clin Immunol       Date:  1994-12       Impact factor: 10.793

View more
  3 in total

Review 1.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 2.  Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.

Authors:  Joshua M Levy; Luke Rudmik; Anju T Peters; Sarah K Wise; Brian W Rotenberg; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2016-08-02       Impact factor: 3.858

3.  Nonsteroidal anti-inflammatory drugs exacerbated respiratory disease - the role of aspirin desensitisation in patients with nasal polyposis.

Authors:  Dorota Jenerowicz; Joanna Szyfter-Harris; Dorota Miêtkiewska-Leszniewska; Magdalena Czarnecka-Operacz; Małgorzata Wierzbicka; Zygmunt Adamski; Witold Szyfter; Małgorzata Leszczyńska
Journal:  Postepy Dermatol Alergol       Date:  2021-09-20       Impact factor: 1.664

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.